References
- Wang Z, Salmon JW, Walton SM. Cost-effectiveness analysis and the formulary decision-making process. J Manage Care Pharm 2004;10:48–59
- Luce BR, Lyles CA, Rentz AM. The view from managed care pharmacy. Health Affairs (Millwood) 1996;15:168–76
- Anon. Redbook 2006: pharmacy’s fundamental reference, 109th ed. [Red Book Drug Topics]. Montvale (NJ): Thomson Healthcare; 2006
- Anon. Physicians desk reference, 60th ed. Montvale (NJ): Thompson PDR; 2006
- Zarate CA, Tohen M, Narendran R. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry 1999;60:232–6
- Bowden CL, Swan AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006;67:1501–10
- Bridle C, Palmer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004;8:1–187
- US prescribing information: Depakote(R) ER, divalproex sodium extended-release tablets. Abbott Laboratories, North Chicago, IL, http://rxabbott.com/pdf/dep3.pdf [accessed 12/27/06. Revised January 2006]
- Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 1989;261:3273–7
- Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63:384–90
- Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159:1927–9
- Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 2004;44:737–42
- Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos 2004;25:345–52
- Dutta S, Zhang Y, Lee LL, O’Dea R. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers. Biopharm Drug Dispos 2004;25: 353–7
- Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analysis from nine trials. Epilepsy Behav 2004;5:746–51
- Drugstore.com. Prescription price checker. www.Drugstore.com [accessed 10/17/06]
- Horne RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol 2003;23:176–81
- Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the ‘top 10’ physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med 2003;45:5–14
- Sajatov M, Gerhart C, Semple W. Association between mood-stabilizing medication and mental health resource use in the management of acute mania. Psychiatr Services 1997;48:1037–41
- Frye MA, Altshuler LL, Szuba MP, et al. The relationship between antimanic agents for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psych 1996;57:17–21
- Keck PE, McElroy SL, Bennett JA. Health-economic implications of the onset of action of antimanic agents. J Clin Psych 1996;57(Suppl 14):13–8
- Zhu B, Tunis SL, Zhao Z, et al. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized 47-week trial. Curr Med Res Opin 2005;21:555–64
- Olie JP, Levy E. Manic episodes: the direct cost of a three-month period following hospitalization. Eur Psychiatry 2002;17: 278–86